Echo Therapeutics, Inc.
ECTE
Other OTC0.00
USD
- -
- -
CIK
0001031927
ISIN
US27876L2060
CUSIP
27876L206
Return %
Stock
S&P500
1Y
- -
17.85
3Y
- -
64.56
5Y
- -
69.89
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Alan W. Schoenbart CPA
- Full Time Employees
- 19
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 99 Wood Avenue South Iselin NJ United States of America
- IPO Date
- Jun 29, 2011
- CIK
- 0001031927
- Website
- echotx.com
- Similar Companies
- Business
- Echo Therapeutics, Inc. (ECTE) develops non-invasive, wireless continuous glucose monitoring (CGM) systems and transdermal skin permeation technologies for diabetes management, wearable health consumer applications, and hospital critical care settings; its core products include the Symphony CGM system, comprising a needle-free skin preparation device, transdermal glucose sensor, battery, and wireless transmitter for on-demand glucose data extraction and delivery of topical pharmaceuticals. Founded in 1989 and headquartered in Iselin, New Jersey, the company targets outpatient diabetes markets, fitness and lifestyle sectors, and medical facilities with operations supported by licensing agreements, including partnerships with Ferndale Pharma Group for skin preparation devices across North America, the UK, South America, Australia, New Zealand, Switzerland, and parts of Europe; Handok Pharmaceuticals for CGM in South Korea; and Medical Technologies Innovation Asia for CGM development, manufacturing, and commercialization in China, Hong Kong, Macau, and Taiwan. Although no major acquisitions, funding rounds, or product launches have occurred in the last 1-2 years, the company maintains its focus on advancing needle-free biosensing platforms amid a near-zero stock valuation as of late 2025, with historical financing such as a $5.1 million convertible notes and warrants placement in 2016 supporting research, development, and general corporate purposes.
Financial Analysis: Echo Therapeutics (OTCMKTS:ECTE) vs. DarioHealth (NASDAQ:DRIO)